You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

~ Buy the RUBRACA (rucaparib camsylate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR RUBRACA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Rubraca

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02740712 ↗	Pharmacokinetic Drug-Drug Interaction Study of Rucaparib	Completed	Clovis Oncology, Inc.	Phase 1	2016-04-01	The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation.
NCT02855944 ↗	ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients	Active, not recruiting	Foundation Medicine	Phase 3	2017-03-01	The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
NCT02855944 ↗	ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients	Active, not recruiting	Clovis Oncology, Inc.	Phase 3	2017-03-01	The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
NCT02873962 ↗	A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib	Recruiting	Bristol-Myers Squibb	Phase 2	2016-11-10	This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
NCT02873962 ↗	A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib	Recruiting	Dana-Farber Cancer Institute	Phase 2	2016-11-10	This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Rubraca

Condition Name

Chart
Table

Condition Name for Rubraca
Intervention	Trials
Fallopian Tube Cancer	5
Ovarian Cancer	4
Epithelial Ovarian Cancer	4
Neoplasms	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Rubraca
Intervention	Trials
Fallopian Tube Neoplasms	6
Ovarian Neoplasms	6
Carcinoma, Ovarian Epithelial	4
Prostatic Neoplasms	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Rubraca

Trials by Country

Map
Table

Trials by Country for Rubraca
Location	Trials
United States	93
Canada	16
Japan	15
Brazil	12
United Kingdom	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Rubraca
Location	Trials
California	6
New York	5
Georgia	5
Florida	4
Pennsylvania	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Rubraca

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Rubraca
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	8
Phase 1/Phase 2	3
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Rubraca
Clinical Trial Phase	Trials
Recruiting	7
Active, not recruiting	7
Completed	5
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rubraca

Sponsor Name

Chart
Table

Sponsor Name for Rubraca
Sponsor	Trials
Clovis Oncology, Inc.	19
Bristol-Myers Squibb	6
Foundation Medicine	3
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Rubraca
Sponsor	Trials
Industry	45
Other	13
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.